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Kidney disease in Uganda: a community
based study
Robert Kalyesubula1,2,6*, Joaniter I. Nankabirwa1, Isaac Ssinabulya1,3, Trishul Siddharthan4, James Kayima1,3,
Jane Nakibuuka2, Robert A. Salata5, Charles Mondo2, Moses R. Kamya1 and Donald Hricik5
Abstract
Background: Chronic kidney disease (CKD) is a major cause of morbidity and mortality in Sub-Saharan Africa (SSA).
The majority of studies on CKD in SSA have been conducted among HIV-infected populations and mainly from
large health facilities. We determined the prevalence of CKD and its predictors among populations in communities
in central Uganda.
Methods: A cross-sectional study was conducted in Wakiso district using multi-stage sampling. Data was collected
on age, sex, socio-economic status, history of alcohol intake, diabetes mellitus, hypertension and smoking.
Measurement of blood pressure, weight and height to determine body mass index (BMI) and investigations
including HIV testing, fasting blood sugar, creatinine and urinalysis were conducted. Logistic regression was used to
estimate the strength of the association between variables and the presence of CKD estimated using the Cockcroft
Gault formula.
Results: A total of 955 participants aged 18–87 years were enrolled into the study. The median age was 31 years
(Interquartile range 24–42) and majority (67%) were female. Up to 21.4% (204/955) had abnormal renal function
with CKD stage 1 in 6.2% (59/955), stage 2 in 12.7% (121/955), stage 3 in 2.4% (23/955), CKD stage 4 in 0% and CKD
stage 5 in 0.1% (1/995). Female gender OR 1.8 (95% Confidence Interval [CI] 1.2–2.8), age >30 years OR 2.2(95% CI 1.
2–3.8) and high social economic status OR 2.1 (95% CI 1.3–3.6) were associated with increased risk of CKD while
BMI > 25Kg/m2 was protective against CKD OR 0.1 (95% CI 0.04–0.2). Traditional risk factors such as HIV-infection,
diabetes mellitus, smoking and alcohol intake were not found to be significantly associated with CKD.
Conclusion: We found a high prevalence of kidney disease in central Uganda. Interestingly the traditional risk
factors associated with CKD previously documented, were not associated with CKD.
Keywords: Chronic kidney disease, Risk factors, Uganda, sub-Saharan Africa
Background
The global burden of non-communicable diseases (NCDs)
continues to increase. The World Health Organization
projects that NCDs will account for 46% of mortality in
sub-Saharan Africa (SSA) by 2030 [1]. Currently, SSA has
a dual burden of both infectious and non-infectious
diseases. Chronic kidney disease (CKD) plays a major
role as a cause and a consequence of other NCDs. A
recent systematic review estimates the current preva-
lence of CKD in sub-Saharan Africa (SSA) at 13.9%
(95% Confidence Interval [CI] 12.2–15.7) [2]. It is
also estimated that by 2030, 70% of worldwide end-
stage renal disease (ESRD) will be in low income
countries like those in SSA [3]. In many countries the
majority of CKD-related studies have focused on
HIV-infected patients [4]. In Uganda, a plurality of
studies conducted in the recent past has focused on
HIV-infected patients with little data available on non
HIV-infected people [5–9]. This study involved partic-
ipants with and without HIV in rural and semi-urban
communities of Uganda.
There are many challenges concerning managing kid-
ney diseases in SSA. First, we currently lack data on the
major risk factors for chronic kidney disease in SSA due
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to lack of renal registries and meticulous longitudinal
studies [10, 11]. The second challenge is that the major-
ity of patients have no symptoms in the early stages of
kidney disease and only present with advanced disease
to health care facilities. In a recent study from a national
referral hospital from Uganda, up to 51% (n = 111) of
patients attending the outpatient nephrology care clinic
had ESRD [12]. This is largely because the risk factors
that could trigger a high index of suspicion for kidney
disease in most of SSA have not been well established
[11]. Once a patient develops end stage kidney disease
there is need for renal replacement therapy irrespective
of the primary cause. Early diagnosis and treatment on
the other hand has been shown to delay or even reverse
CKD but this is largely driven by screening for known
risk factors and treating them [13, 14].
We determined the prevalence for CKD and associated
factors in both rural and urban based community set-
tings of Wakiso, Uganda using a cross-sectional design.
We also compared the prevalence generated using the
different glomerular estimation formulae including the
Chronic Kidney Disease -Epidemiology Consortium
equation (CKD-Epi), the Cockcroft Gault (CG) and the
Modification of Diet in Renal Disease (MDRD) to estab-
lish a baseline differences between the formulae.
Methods
Between August 2012 and August 2013, MEPI-CVD
(Medical Education Partnership Initiative on Cardiovas-
cular Diseases) conducted a cross-sectional community
based survey in an urban and a rural sub-county in
Wakiso district to determine the prevalence and risk
factors for cardiovascular disease [15]. The detailed
methods of the MEPI-CVD survey have been described
elsewhere [15, 16]. All the sub-counties in Wakiso dis-
trict were stratified into rural and urban and then one
sub-county was chosen from each stratum by simple
random sampling. One urban sub-County (Nansana
Town Council) was randomly selected out of 5 urban
sub-counties and one rural sub-County (Busukuma) was
randomly selected out of 13 rural sub-counties in
Wakiso district (see Fig. 1. Study Area: Map showing
rural area of Busukuma and periurban area of Nansana,
Wakiso District, Uganda. Caption: This image was modi-
fied from Wikimedia Commons for maps by Dr. Robert
Kalyesubula). All households and other key features in
the selected sub-counties were mapped and enumerated
to generate a sampling frame for the survey. Household
locations were mapped using hand-held global position-
ing system (GPS) receivers. A total of 5,420 households
was selected to participate in the survey using a list
randomly generated from the household enumeration
database. In each of the selected households, one adult
(18 years or older) was selected to participate in the sur-
vey. Households without an adult were excluded leaving
a total of 4,952 participants in the study. Following in-
formed consent, a structured standard questionnaire
adopted from WHO STEPS was administered to the
household respondents. The questionnaire was adminis-
tered through face-to-face personal interviews in a research
clinic, ensuring a setting that provided maximum privacy
to conduct the interview. The data collected included:
demographics (age, sex, and address), diet, tobacco and
alcohol consumption and medical history, as well as smoke
Fig. 1 Map of Uganda Showing urban and rural areas from Wakiso district. This map was adopted and modified by Dr Robert Kalyesubula
from wikimedia
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exposure, socio-economic status and family history of
NCDs. The researchers also undertook physical mea-
surements for blood pressure, height, weight to obtain
the BMI, waist circumference and hip circumference to
obtain the waist-hip ratio following standard protocols.
Blood samples were obtained via venous phlebotomy for
investigations including; HIV, fasting blood sugar and full
blood counts. Urine analysis was done using a dipstick.
All participants from the primary MEPI-CVD linked study
with complete data including urine protein were eligible
for the CKD study.
During the MEPI-CVD survey, blood samples were
stored as plain serum in microvials in a negative 80 °C
freezer at the MBN Clinical Laboratory in Kampala,
Uganda. The MBN Clinical laboratory is an internation-
ally accredited laboratory with quality standards for both
real time and retrospective specimen analysis. We re-
trieved the stored samples for the randomly selected
1000 participants who met the inclusion criteria and
tested their creatinine levels using the Cobas Auto
Analyzer (Roche Diagnostics, North America) with a
standard reference range of; 66 -106umol/L. Of the 1000
participants 955 had complete samples. The creatinine
level measured for each of the participants was used to
estimate the glomerular filtration rate using the
Cockcroft-Gault formula adjusted for BMI in accordance
with previous studies performed in Uganda [6].
Statistical analysis
To determine the prevalence of kidney disease, we used
the proportion of patients with proteinuria of > 1+ with an
estimated glomerular filtration rate of less than 90mls/
min/1.73 m2 and divided this by the total number of
patients recruited in the study. Proteinuria was graded as:
negative (less than 10 mg per dL), trace (10 to 20 mg per
dL), 1+ (30 mg per dL), 2+ (100 mg per dL), 3+ (300 mg
per dL) or 4+ (1,000 mg per dL) [17]. Chronic kidney dis-
ease was further staged according severity based on the
National Kidney Foundation guidelines [18]. We defined
kidney disease as a creatinine clearance of less than
90mls/min/1.73 m2 and chronic kidney disease as a cre-
atinine clearance of less than 60mls/min/1.73 m2. Z-
scores were generated to compare the proportions at each
severity level using the CKD-Epi values as reference [19].
The four categories of the Socio-economic Score (SES)
were derived from conducting Principle Component
Analysis (PCA) on a statistical software using variables
relating to household infrastructure and property own-
ership. Logistic regression was used to identify factors
associated with having kidney disease and odds ratios
with their 95% confidence intervals as the measures of
association. We adhered to the STROBE guidelines/
methodology for reporting our findings.
Ethics
Ethical approval was obtained from Makerere University
School of Medicine Research and Ethics Committee as
well as the Uganda National Council for Science and
Technology (UNCST). Patients provided informed con-
sent for the parent study (MEPI-CVD study) and future
use of the samples which were stored. Administrative
permission to use the stored samples was also obtained
from the Principal Investigator of the MEPI-CVD study.
Results
Characteristics of participants
Of 1000 patients screened from the MEPI-CVD study,
955 (96%) had complete data to determine the prevalence
and associated factors for CKD. The remaining 45 partici-
pants had incomplete samples for measurement of cre-
atinine but did not differ significantly from those included
in the study. We additionally compared the demographics
of the 955 participants included for the CKD study with
the 3,997 excluded from the original study and found no
differences in demographic variables.
Of the 955 participants, the majority (67%, n = 640)
were female and more than two-thirds (73%, n = 696)
were peri-urban residents. The median age of the partic-
ipants was 31 years (IQR, 24–42). A total of 93 (9.7%)
participants were HIV-infected, while one in four (25%,
n = 239) were hypertensive-defined as being on drugs for
hypertension or having a systolic blood pressure ≥
140 mmHg and/or diastolic blood pressure ≥ 90 mmHg
at three consecutive measurements. The majority of
participants had never smoked (90%, n = 862) nor used
alcohol (88%, n = 841). A summary of selected characteris-
tics of the participants by gender is presented in Table 1.
The rural and peri-urban communities significantly dif-
fered on all demographic factors except HIV- infection
status and presence of proteinuria. Participants from peri-
urban communities were more likely to be younger,
poorer, and normotensive with higher BMI (see Table 2).
Prevalence of kidney disease
The prevalence of kidney disease in this study popula-
tion was 15.2% (n = 145) using the Cockcroft Gault for-
mula. The prevalence according to CKD stages were;
CKD stage 1 in 6.2% (n = 59), stage 2 in 12.7% (n = 121),
stage 3 in 2.4% (n = 23), stage 4 in 0% (n = 0) and stage 5
(end stage kidney disease) in 0.1% (n = 1). A total of
6.2% (59) participants had normal glomerular filtration
rates but with urinary abnormalities. More than a fifth
(21.4%, n = 204) of the participants had renal abnormal-
ities of creatinine and urinalysis detected (see Fig. 2). Of
those with urine abnormalities 3 (0.3%) had proteinuria
and 55 (5.6%) participants had hematuria.
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Comparison of the prevalence of stages of CKD using the
different formulae for estimation of glomerular filtration rate
Sensitivity analysis was done using different formulae.
The average glomerular filtration rates did not differ
(see Table 3). Using the three internationally recog-
nized estimated glomerular filtration rate (eGFR) for-
mulae namely: Chronic Kidney Disease -Epidemiology
Consortium equation(CKD-Epi), Modification of Diet in
Renal Disease (MDRD) and the Cockcroft Gault (CG);
more than a fifth of participants had kidney abnormalities.
The prevalence for stage 1 kidney disease was similar
using the three formulae. Significant differences in preva-
lence were noted for stage 2 kidney disease with CKD-Epi
detecting 2.9% (n = 28), CG at 12.7% (n = 121) and MDRD
showing 5.9% (n = 57) (p < 0.001). For advanced kidney
disease stage 4 and 5; there were no patients with CKD
identified by the CKD-Epi or MDRD formulae but one
patient (0.1%) was identified to have ESRD with the CG
formula (see Table 4).
Risk factors for kidney disease
Being female OR 1.8 (95% CI 1.2–2.8), age over 30 years
OR 2.2 (95% CI 1.2–3.8) and a high social economic sta-
tus (least poor) OR 2.1 (95% CI 1.3–3.6) were associated
with kidney disease. The odds for age increased expo-
nentially for higher age groups. Body mass index (BMI)
above 25 Kg/m2 was protective against CKD OR 0.1
(95% CI 0.04–0.2).
On bivariate analysis, participants from rural Busukuma
were three times OR 3.2 (95% CI 2.2–4.5) more likely to
have kidney disease compared to their peri-urban counter-
parts from Nansana. However, this association diminished
on adjusting for confounders including age and social eco-
nomic status. Similarly, on bivariate analysis, participants
with hypertension were 2 times more likely to have kidney
disease but this was largely confounded by age and body
mass index (see Table 5). The traditional risk factors of
Table 1 Baseline characteristics of study participants from
Wakiso, Uganda by gender
Characteristic Total
N = 955
Males
(N = 315)
Female
(N = 640)
Median age (IQR) 31 (24–42) 30 (24–40) 32 (25–43)
Age group
18–29 410 (42.9) 151 (47.9) 259 (40.5)
30–39 261 (27.3) 78 (24.8) 183 (28.6)
40–49 136 (14.2) 48 (15.2) 88 (13.7)
50–59 73 (7.6) 17 (5.4) 56 (8.8)
60+ 75 (7.9) 21 (6.7) 54 (8.4)
Sub-county
Nansana Town
Council
696 (72.9) 213 (67.6) 483 (75.5)
Busukuma 259 (27.1) 102 (32.4) 157 (24.5)
SESa
Poorest 226 (23.7) 75 (23.8) 151 (23.6)
Poor 225 (23.6) 85 (26.9) 140 (21.9)
Less poor 261 (27.3) 80 (25.4) 181 (28.3)
Least poor 243 (25.4) 75 (23.8) 168 (26.2)
Median Weight (IQR) 61 (53–71) 61 (56–69) 60 (52–72)
BMI groups
Underweight 52 (5.5) 24 (7.6) 28 (4.4)
Normal 544 (56.9) 230 (73.0) 314 (49.1)
Overweight 231 (24.2) 49 (15.6) 182 (28.4)
Obese 128 (13.4) 12 (3.8) 116 (18.1)
HIV-Infection
No 862 (90.3) 289 (91.8) 573 (89.5)
Yes 93 (9.7) 26 (8.2) 67 (10.5)
Diabetic n (%)
Normal 733 (76.8) 271 (86.0) 462 (72.2)
Impaired tolerance 173 (18.1) 38 (12.1) 135 (21.1)
Diabetic 49 (5.1) 6 (1.9) 43 (6.7)
Hypertension n (%)
Normal 716 (75.0) 235 (74.6) 481 (75.2)
Hypertensive 239 (25.0) 80 (25.4) 159 (24.8)
Smoking, n (%)
Never smoked 862 (90.3) 259 (82.2) 603 (94.2)
Previously smoker 39 (4.1) 17 (5.4) 22 (3.4)
Current smoker 54 (5.6) 39 (12.4) 15 (2.3)
Alcohol use n (%)
None 841 (88.1) 254 (80.6) 587 (91.7)
Mild 33 (3.5) 16 (5.1) 17 (2.6)
Moderate 52 (5.4) 25 (7.9) 27 (4.2)
Heavy 29 (3.0) 20 (6.4) 9 (1.4)
Mean serum
creatinine (SD)
0.66 (0.18) 0.75 (0.2) 0.62 (0.2)
Table 1 Baseline characteristics of study participants from
Wakiso, Uganda by gender (Continued)
CCr (mls/min/1.73 m2)median (IQR)
CG 124 (101–158) 124 (103–157) 124 (101–160)
MDRD 140 (116–177) 149 (123–188) 136 (112–170)
CKD-Epi 138 (122–152) 141 (128–155) 136 (119–150)
Proteinuria (urine protein≥ 1+)
No 952 (99.7) 314 (99.7) 638 (99.7)
Yes 3 (0.3) 1 (0.3) 2 (0.3)
Abbreviations: BMI Body mass index, CG Cockroft Gault, CCr creatinine
clearance, CKD-EPI Chronic Kidney Disease Epidemiology Consortium equation,
IQR Interquartile range, MDRD 4-variable Modification of Diet in Renal Disease
equation, SES social economic score
aSocio-economic Score (SES) derived from conducting Principle Component
Analysis (PCA) on a statistical software using variables relating to household
infrastructure and property ownership
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HIV-infection, diabetes mellitus, smoking and alcohol in-
take were not significantly associated with kidney disease
in this study (see Table 5).
We also run an analysis using the CKD-Epi and MDRD
for CKD associated factors (data not shown). Female sex,
age above 30 years, and socio-economic status were found
to be associated with CKD using the MDRD and CG for-
mulae. Age above 30 years and hypertension were found
to be associated with CKD using the CKD-Epi formula.
Diabetes mellitus was not consistently identified as a risk
factor for kidney disease with MDRD identifying it as a
significant factor while CG and CKD-Epi did not.
Discussion
We found a high prevalence of kidney disease at 15.2%,
CKD of 2.5% with ESRD in 0.1% in Wakiso district,
Uganda. The high prevalence of kidney disease in rural
and peri-urban areas highlights the current burden of
NCDs. High prevalence of kidney disease has been iden-
tified in other areas of SSA; in Tanzania the prevalence
of CKD was found to be 7.0% overall with 15.2% in the
urban population while a systematic review estimates an
overall prevalence of CKD in SSA at 13.9% [2, 10]. These
findings have far reaching consequences to a developing
Table 2 Baseline characteristics of study participants from
Wakiso, Uganda by sub-county
Characteristic Nansana
(N = 696)
Busukuma
(N = 259)
p-value
Median age (IQR) 30 (24–38) 38 (27–50) <0.001
Age group
18–29 335 (48.1) 75 (28.9) <0.001
30–39 202 (29.0) 59 (22.8) 0.056
40–49 80 (11.5) 56 (21.6) <0.001
50–59 44 (6.3) 29 (11.2) <0.011
60+ 35 (5.0) 40 (15.4) <0.001
Sex
Male 213 (30.6) 102 (39.4) <0.001
Female 483 (69.4) 157 (60.6)
SES
Poorest 205 (29.4) 21 (8.1) <0.001
Poor 192 (27.6) 33 (12.8) <0.001
Less poor 126 (18.1) 135 (52.1) <0.001
Least poor 173 (24.9) 70 (27.0) 0.508
Median Weight (IQR) 62 (55–72) 58 (50–66) <0.001
BMI groups
Underweight 31 (4.5) 21 (8.1) 0.029
Normal 365 (52.4) 179 (69.1) <0.001
Overweight 186 (26.7) 45 (17.4) 0.003
Obese 114 (16.4) 14 (5.4) <0.001
HIV-Infection
No 622 (89.4) 240 (92.7) 0.126
Yes 74 (10.6) 19 (7.3)
Diabetic n (%)
Normal 516 (74.2) 217 (83.8) 0.002
Impaired tolerance 139 (19.9) 34 (13.1) 0.015
Diabetic 41 (5.9) 8 (3.1) 0.082
Hypertension n (%)
Normal 535 (76.9) 181 (69.9) 0.026
Hypertensive 161 (23.1) 78 (30.1)
Smoking, n (%)
Never smoked 631 (90.7) 231 (89.2) <0.001
Previously smoker 31 (4.4) 8 (3.1) 0.365
Current smoker 34 (4.9) 20 (7.7) 0.096
Alcohol use n (%)
None 622 (89.4) 219 (84.6) 0.042
Mild 23 (3.3) 10 (3.9) 0.652
Moderate 31 (4.5) 21 (8.1) 0.029
Heavy 20 (2.9) 9 (3.5) 0.632
Mean serum
creatinine (SD)
0.65 (0.54–0.76) 0.67 (0.53–0.81) 0.297
Table 2 Baseline characteristics of study participants from
Wakiso, Uganda by sub-county (Continued)
CG 130 (87.7–161.5) 112 (88.9–142.5) <0.001
MDRD 141 (117.4–177.5) 139 (108.5–174.7) 0.859
CKD-Epi 139 (125.1–153.1) 132 (114.9–147.1) <0.001
Proteinuria (urine protein≥ 1+)
No 693 (99.6) 259 0.308
Yes 3 (0.4) 0
Socio-economic Score (SES) derived from conducting Principle Component
Analysis (PCA) on a statistical software using variables relating to household
infrastructure and property ownership
Abbreviations: BMI Body mass index, CG Cockroft Gault, CCr creatinine
clearance, CKD-EPI Chronic Kidney Disease Epidemiology Consortium equation,
IQR Interquartile range, MDRD 4-variable Modification of Diet in Renal Disease
equation, SES social economic score
Fig. 2 Prevalence of kidney disease by stage
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country of 34.9 million people [20] with few trained spe-
cialist and few dialysis centres to support the increased
burden of kidney disease [21]. The cost of caring for
patients with ESRD is extremely high. Hemodialysis
which is one of the available means for management of
ESRD in SSA has been estimated to cost between 7,000
and 55,000 US dollars per patient per year depending on
whether the facility is private or government supported
[21–23]. For a perspective, the average household (aver-
age of 5 persons) monthly income for Ugandans is
estimated at a meager 78 US dollars per month with
an average monthly expenditure of 12 US dollars on
healthcare [24, 25].
There was a significant difference in the prevalence
and stages of chronic kidney disease when different for-
mulae were used to estimate the glomerular filtration
rate. Similar findings have been noted in other studies. A
study by Wyatt [26] found that CG over estimates the
rate of CKD while Kaze noted different rates of CKD
ranging from 4.4 to 8.8% depending on which formula
was used [27]. The CKD-Epi has been found to be more
accurate in patients with near normal kidney function
[28]. However, highest correlation in clinical practice
was found with CG when corrected for low body mass
[29]. The equations used to determine the estimated
glomerular filtration rate (eGFR) have not been validated
among populations in SSA [30, 31]. Thus, it is still difficult
to determine the optimal eGFR formula to use in estab-
lishing the prevalence and risk factors for CKD
particularly in resource-limited settings. Variability in for-
mulae for diagnosing CKD has far reaching implications
as patients may be misclassified and given the wrong diag-
nostic stage which may lead to anxiety and unnecessary
treatments if the diagnostic stage is worse than the true
GFR. Conversely, patients may miss treatment if they are
given a more favourable diagnostic stage than their true
GFR. It is therefore critical that a true GFR is determined
for each patient. Resolving this issue will require larger
population-based studies in SSA to determine the true
GFR formula for this region.
Age (above thirty years), female gender, and high social
economic status were associated with increased risk of kid-
ney disease. This has been found by other studies from
Africa [2, 27]. In contrast, low socioeconomic status has
been associated with both development and progression of
CKD in Europe and United States of America [25, 32]. This
may be attributed to environmental and lifestyle factors
which differ across the different regions [33]. In general, the
prevalence of CKD is greater among women than in men
across all ages from both developed countries and SSA
[34]. The difference in CKD prevalence between males and
females could be explained by the fact that women have
less muscle mass and there are differences in the glomeru-
lar structure and hormone metabolism which may play a
role in this gender disparity [35]. We did not find a signifi-
cant difference in prevalence between peri-urban Nansana
Town Council and rural Busukuma. This is in contrast to
the study in neighbouring Tanzania where rural communi-
ties had a low prevalence at 2.0% compared with the urban
in 15.7% [10]. The complicated association between age,
poverty and BMI in urban and rural areas may have had an
impact on the results between these two communities.
Table 3 Glumerular filtration rates by different formulas
eGFR Median, IQR (males) Median, IQR (Females) Median, IQR (Overall)
eGFR-CG 124.1 (102.6–157.2) 123.6 (101.1–159.5) 123.9 (101.4–158.0)
eGF- MDRD 148.9 (122.6–187.9) 135.6 (111.7–170.1) 140.5 (115.8–176.6)
eGFR- CKD-Epi 140.8 (127.5–155.0) 135.8 (119.4–149.6) 137.6 (121.9–152.1)
eGFR estimated glomerular filtration rate, all measurements in mls/min/1.73 m2, CG Cockroft Gault, MDRD 4-variable Modification of Diet in Renal Disease equa-
tion, CKD-EPI Chronic Kidney Disease Epidemiology Consortium equation
Table 4 Chronic Kidney Disease stages according to the National Kidney Foundation, using Cockroft Gault and Modification of Diet
in Renal Disease Glomerular Filtration Rate estimations compared with CKD-Epi
GFR estimation CKD-Epi n (%)
N = 955
CG est n (%)
N = 955
p (CG vs CKD –Epi) MDRD n (%) p (MDRD vs CKD –Epi)
0 ≥90, without urine dipstick abnormality 861 (90.2) 751 (78.6) <0.0001 834 (87.3) 0.045
1 ≥ 90, with urine dipstick abnormality 64 (6.7) 59 (6.2) 0.656 62 (6.5) 0.860
2 60–89, with urine dipstick abnormality 28 (2.9) 121 (12.7) <0.0001 57 (5.9) 0.001
3a 45–59.9, with or without urine dipstick abnormality 1 (0.1) 15 (1.6) 0.0004 1 (0.1) 1.000
3b 30–44.9, with or without urine dipstick abnormality 1 (0.1) 8 (0.8) 0.022 1 (0.1) 1.000
4 15–29.9, with or without urine dipstick abnormality 0 0 1.000 0 1.000
5 < 15, with or without urine dipstick abnormality 0 1 (0.1) 0.328 0 1.000
Abbreviations: CG Cockroft Gault, CKD-Epi Chronic Kidney Disease Epidemiology Consortium equation, e-GFR estimated glomerular filtration rate, MDRD 4-variable
Modification of Diet in Renal Disease equation
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Table 5 Association between kidney disease (Cockcroft-Gault formula) and different predictor variables
Characteristic n/N (%) Unadjusted OR (95% CI) p-value Adjusted OR (95% CI) p-value
Sub-county
Nansana 74/696 (10.6) 1 1
Busukuma 71/259 (27.4) 3.2 (2.2–4.5) <0.001 1.5 (0.99–2.4) 0.053
Sex
Male 41/315 (13.0) 1 1
Female 104/640 (16.2) 1.3 (0.2–1.9) 0.191 1.8 (1.2–2.8) 0.010
Age group
18–29 28/410 (6.8) 1 1
30–39 27/261 (10.3) 1.6 (0.9–2.7) 0.108 2.2 (1.2–3.8) 0.009
40–49 32/136 (23.5) 4.2 (2.4–7.3) <0.001 4.3 (1.2–3.8) <0.001
50–59 17/73 (23.3) 4.1 (2.1–8.1) <0.001 5.5 (2.4–7.8) <0.001
60+ 41/75 (54.7) 16.5 (9.1–29.8) <0.001 17 (8.4–35.4) <0.001
SES
Poorest 25/226 (11.1) 1
Poor 21/225 (9.3) 0.8 (0.4–1.5) 0.545
Less poor 55/261 (21.1) 2.1 (1.3–3.6) 0.003
Least poor 44/243 (18.1) 1.8 (1.1–3.0) 0.033
BMI groups
Underweight 21/52 (40.4) 1 1
Normal 105/544 (19.3) 0.3 (0.2–0.6) 0.001 0.4 (0.2–0.8) 0.008
Overweight 18/231 (7.8) 0.1 (0.05–0.3) <0.001 0.1 (0.04–0.2) <0.001
Obese 1/128 (0.8) 0.01 (0.002–0.09) <0.001 0.01 (0.001–0.1) <0.001
HIV-Infection
No 130/862 (15.1) 1
Yes 15/93 (16.1) 1.1 (0.6–1.9) 0.789
Diabetic
Normal 106/733 (14.5) 1 1
Impaired tolerance 29/173 (16.8) 1.2 (0.8–1.9) 0.445 1.2 (0.7–2.0) 0.544
Diabetic 10/49 (20.4) 1.5 (0.7–3.1) 0.260 2.4 (0.98–5.8) 0.055
Hypertension
Normal 92/716 (12.9) 1 1
Hypertensive 53/239 (22.2) 1.9 (1.3–2.8) 0.001 1.2 (0.7–1.9) 0.474
Smoking
Never smoked 133/862 (15.4) 1
Previously smoker 3/39 (7.7) 0.5 (0.1–1.5) 0.198
Current smoker 9/54 (16.7) 1.1 (0.5–2.3) 0.808
Alcohol use
None 132/841 (15.7) 1
Mild 2/33 (6.1) 0.3 (0.1–1.5) 0.150
Moderate 8/52 (15.4) 0.9 (0.4–2.1) 0.952
Heavy 3/29 (10.3) 0.6 (0.2–2.1) 0.438
Age-group confounds HT, BMI confounds HT
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Diabetes mellitus, smoking and alcohol intake were
not key factors associated with kidney disease in this
study population, contrary to previous findings. This
may be due the fact that the majority of participants did
not report use of alcohol or smoking. In a recently com-
pleted national survey for diabetes in Uganda, only 1.4%
(95% CI 0.9–1.9%, N = 3689) participants had diabetes
mellitus [36]. The low prevalence of these well known
risk factors for CKD in our participants makes any com-
ment of their impact difficult to ascertain. In a study by
Stanifer et al., half of the cases of CKD (49.1%) were not
associated with any of the measured risk factors of
hypertension, diabetes, or HIV-infection [10]. In devel-
oped countries and worldwide, the majority of kidney
disease is due to diabetes mellitus followed by hyperten-
sion [37]. It is thus still unclear as to what may be driv-
ing the high levels of kidney disease in the rural and
semi-urban areas of SSA. Future research needs to look
into the peculiar drivers of CKD in SSA. Hypertension
and diabetes mellitus can easily be diagnosed even at the
lower facility levels. But if there are other unknown
causes such as glomerular (especially post-infectious)
and interstitial renal diseases driving the epidemic of
kidney disease in Uganda, these need to be urgently iden-
tified so that appropriate steps to prevent progression to
end-stage renal disease can be effected. Treatment of
ESRD is not clinically and economically feasible for most
low- and middle-income countries [38].
Our study had several strengths. This was a large com-
munity based survey, an attribute that is likely to give a
proxy estimate of the burden of kidney disease in
Uganda. In addition, our study population was both
rural and semi-urban and therefore in a true epidemio-
logical transition. The results of our study can therefore
be generalized to many populations on the African con-
tinent that are in a similar transition. We also compared
the three e-GFR estimation methods and highlighted the
significant differences that exist between them which
may have far reaching consequences to patient care.
However, our study also had a few limitations. The pri-
mary study was a survey, cross sectional in nature and
some data on key parameters for establishing chronic
kidney disease like the abdominal ultrasound scan were
missing. We used proteinuria as a surrogate marker well
aware that it may be affected by other causes like urinary
tract infections among others. Furthermore, proteinuria
rather than microalbuminuria was used for this study. In
addition, we were also not able to determine whether
the kidney dysfunction was acute or chronic because we
did not have repeat (>3 month) creatinine. Nevertheless,
we believe that this study will create awareness on the
magnitude of kidney disease in Uganda and hopefully
stimulate further research into the underlying etiology
and set in motion ways to prevent it.
Conclusion
We found a high prevalence of kidney disease in Uganda
which could not be explained by the traditional causes
of CKD and noted significant levels of disagreement in
the formulae used to estimate glomerular filtration rates.
Further studies are needed to characterize the drivers of
kidney disease beyond diabetes and hypertension as the
prevalence of these diseases continues to rise.
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